RBC Europe’s Haemonetics HAE Stock Holding History

RBC Europe’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$8K	Sell	130 -200	-61%	-$11.8K	﹤0.01%	523
2022 Q1	$21K	Hold	330	–	–	﹤0.01%	447
2021 Q4	$18K	Sell	330 -7,728	-96%	-$471K	﹤0.01%	470
2021 Q3	$569K	Hold	8,058	–	–	0.02%	189
2021 Q2	$537K	Sell	8,058 -868	-10%	-$61.4K	0.02%	195
2021 Q1	$991K	Sell	8,926 -411	-4%	-$50.9K	0.05%	140
2020 Q4	$1.11M	Hold	9,337	–	–	0.06%	131
2020 Q3	$815K	Sell	9,337 -340	-4%	-$29.7K	0.05%	137
2020 Q2	$867K	Hold	9,677	–	–	0.07%	130
2020 Q1	$964K	Sell	9,677 -973	-9%	-$106K	0.1%	105
2019 Q4	$1.22M	Hold	10,650	–	–	0.11%	107
2019 Q3	$1.34M	Hold	10,650	–	–	0.13%	101
2019 Q2	$1.28M	Hold	10,650	–	–	0.13%	105
2019 Q1	$932K	Hold	10,650	–	–	0.1%	113
2018 Q4	$1.07M	Hold	10,650	–	–	0.14%	97
2018 Q3	$1.22M	Sell	10,650 -69	-0.6%	-$7.14K	0.14%	107
2018 Q2	$961K	Sell	10,719 -250	-2%	-$21.1K	0.11%	114
2018 Q1	$802K	Sell	10,969 -500	-4%	-$34.3K	0.1%	122
2017 Q4	$666K	Hold	11,469	–	–	0.08%	134
2017 Q3	$515K	Buy	+11,469	New	+$477K	0.07%	149

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's HAE Position: Q2 2022 in Review

RBC Europe reduced its Haemonetics (HAE) stake by 61% in Q2 2022, selling an estimated $11.8K and leaving 130 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

RBC Europe first reported a position in HAE in Q3 2017 and has held it in 20 quarters since. The position peaked at $1.34M in Q3 2019. 241 funds tracked by Wall St. Rank hold HAE as of Q2 2022.

RBC Europe held 130 shares of Haemonetics worth $8K as of Q2 2022.
RBC Europe sold 200 Haemonetics shares in Q2 2022, an estimated $11.8K.
Haemonetics made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #523 holding.
RBC Europe first reported a position in Haemonetics in Q3 2017 and has held it in 20 quarters since.
RBC Europe's Haemonetics position peaked at $1.34M in Q3 2019.
241 funds tracked by Wall St. Rank held Haemonetics as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.